Full Mouth Restoration on Dental Implants Utilizing Titanium Laser-Welded Frameworks

In today's dental literature, most frequently, esthetics are addressed with fixed restorations. This article will illustrate the opportunity to provide our patients with very good esthetic outcomes with a hopeless dentition utilizing dental implants, laser-welded titanium components, and characterized acrylic resin prostheses. The definitive prostheses provide excellent facial support, phonetics, esthetics, smile line, and function. The steps in such a treatment will be presented from the clinical to dental laboratory procedures.

CLINICAL SIGNIFICANCE

Incorporating newer technology into our patient treatment plans, which increasingly includes dental implants, may allow more time-efficient, esthetic, predictable, and reliable treatment. Laser-welded titanium frameworks offer many advantages for the patient, clinician, and dental technician, which are illustrated.     

Synthesis of phosphotyrosine-containing peptides by the solid-phase method

A practical and convenient procedure for making phosphotyrosine-containing peptides by the solid-phase method was developed. Phosphotyrosine was incorporated via Boc-Tyr(PO₃Bzl₂)-OH. The completed peptide was cleaved from the solid support by treatment with 1 M TMSBr-thioanisole-TFA. By gel-phase ³¹P-NMR spectroscopy we found that one of the benzyl protecting groups on phosphate was completely removed by two consecutive runs of Boc deprotection with 50% TFA-DCM. However, the other benzyl group remained intact throughout the synthesis (35 cycles).     

Use of a super active luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia

Summary. A luteinizing hormone releasing hormone agonist, d-Ser(But)⁶des Gly¹⁰-LHRH ethylamide, was administered intranasally to four women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side-effects, although the pattern of loss returned to pretreatment levels within 2 months of ceasing therapy.